Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
Moderna's shares surged 131% after the biotech scored a Phase 3 trial win against the standard of care for cancer. The stock rally left short sellers with $4.8 billion in losses.
DeFi Intel is an entity-graph aggregator: we curate, tag and link crypto news to a typed knowledge graph of protocols, tokens, people and incidents. We do not republish the full article body. Use the link above to read the original report at Decrypt.
Discussion
Comments are reviewed before publication.
Want the full article?
Continue reading on Decrypt →
No comments yet.